The Centers for Medicare and Medicaid Services has unveiled its list of the first 10 prescription drugs subject to price negotiations under the Inflation Reduction Act. The list includes popular blood thinners, insulin products and diabetes drugs.

Under the act, Medicare is now able to directly negotiate the prices of prescription drugs covered under Medicare Part D. The negotiations will be ongoing through 2024 with the new prices effective beginning in 2026.

“Our goal with these negotiations is to improve access to some of the costliest drugs for millions of people with Medicare while driving competition and innovation,” CMS Administrator Chiquita Brooks-LaSure said in a statement.

The first 10 drugs selected for negotiation are:

• Eliquis, a blood thinner used to prevent blood clots
• Enbrel, a rheumatoid arthritis, psoriasis drug
• Entresto, a heart failure drug
• Farxiga, a drug for diabetes, heart failure and chronic kidney disease
• Fiasp and NovoLog, for diabetes
• Imbruvica, a drug for blood cancers
• Januvia, a diabetes drug
• Jardiance, a diabetes drug, heart failure drug
• Stelara, a drug for psoriasis and Crohn’s disease
• Xarelto, a blood thinner

Medicare enrollees taking the 10 drugs paid a total of $3.4 billion in out-of-pocket costs in 2022 for these drugs, according to the agency. In addition, they accounted for $50.5 billion in total Medicare Part D spending in a 12-month time frame ending in May.

In the future, CMS will select negotiations for up to 15 drugs for 2027 and then 15 additional ones for 2028 then up to 20 more drugs for each year after that.